亿帆医药(002019.SZ)取得一项药品注册证书

Core Viewpoint - The company received approval for its injectable drug Isavuconazole from the National Medical Products Administration, marking a significant milestone in its product portfolio [1] Company Summary - Yifan Pharmaceutical's wholly-owned subsidiary Hefei Yifan Biopharmaceutical Co., Ltd. obtained the drug registration certificate for injectable Isavuconazole on September 15, 2025 [1] - Isavuconazole is an antifungal medication indicated for the treatment of invasive infections in adult patients, specifically invasive aspergillosis and invasive mucormycosis [1]